Related Experiment Video
Updated: Aug 10, 2026
Isolating Human Peripheral Blood Mononuclear Cells and CD4+ T cells from Sézary Syndrome Patients for Transcriptomic Profiling
Published on: October 14, 2021
Production of a cytotoxin from phorbol myristate acetate-treated human promyelocytes
Abstract:
Human promyelocytic leukemia cells, when differentiated into macrophages by treatment with phorbol myristate acetate, secrete a cytolytic factor. Enhanced production was achieved when the cultures were treated with bacterial lipopolysaccharide (LPS). Production of the factor was inhibited when cultures were treated with dactinomycin immediately after LPS treatment. Tritirachium alkaline proteinase treatment inactivated the factor, indicating that it has an essential protein moiety. The molecular weight was found to be approximately 40,000 by Sephacryl S-200 gel filtration. The factor was stable at 56 degrees C for 30 minutes, but 80% of the activity was inactivated at 70 degrees C in 30 minutes. The factor was destroyed (96%) by dialysis against 0.01 M HCl (pH 2) for 14 hours. The cytolytic factor had little activity on normal fibroblasts, but it was able to significantly kill transformed cells in vitro.
Insights
Human leukemia cells differentiated into macrophages produce a cytolytic factor, enhanced by bacterial lipopolysaccharide (LPS). This protein factor selectively kills transformed cells in vitro, showing potential for cancer research.
Area of Science:
- Cell Biology
- Immunology
- Biochemistry
Background:
- Human promyelocytic leukemia cells can differentiate into macrophages.
- Macrophages are known to secrete various factors involved in cellular processes.
Purpose of the Study:
- To investigate the production and characteristics of a cytolytic factor secreted by differentiated human leukemia cells.
- To determine the factor's selectivity towards transformed cells versus normal cells.
Main Methods:
- Differentiating human promyelocytic leukemia cells using phorbol myristate acetate.
- Stimulating factor production with bacterial lipopolysaccharide (LPS) and inhibiting with dactinomycin.
- Characterizing the factor using proteinase treatment, gel filtration (Sephacryl S-200), thermal stability assays, and pH stability assays.
- Assessing the factor's cytolytic activity against normal fibroblasts and transformed cells in vitro.
Main Results:
- Differentiated macrophages secrete a cytolytic factor, with production enhanced by LPS.
- Factor production was inhibited by dactinomycin, suggesting a protein synthesis requirement.
- The factor has a molecular weight of approximately 40,000 Da and contains an essential protein moiety.
- The factor demonstrated stability at 56°C but was inactivated at 70°C, and was destroyed by acidic conditions (pH 2).
- The cytolytic factor exhibited significant killing activity against transformed cells but minimal activity against normal fibroblasts.
Conclusions:
- Human leukemia cells differentiated into macrophages secrete a heat-stable, acid-labile protein cytolytic factor.
- This factor selectively targets and kills transformed cells in vitro, indicating potential therapeutic applications.
